The “Next Bitcoin”? 10 CENT Crypto Set to Explode

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Lukas Scheibler Biography and Net Worth

Insider of Apellis Pharmaceuticals

Dr. Scheibler joined Apellis in April 2018 as executive vice president for research and translational medicine. In this role, he is responsible for creating and managing all preclinical research projects and advancing them into clinical development to establish proof of concept. Dr. Scheibler is an R&D professional with in-depth experience in drug development. He most recently was head of R&D at Acucela (a Seattle-based startup) and had a 13-year career in research and development, business development, and clinical development at Novartis. He holds a PhD degree from the University of Lausanne, Switzerland, and had postdoctoral training at Harvard Medical School.

What is Lukas Scheibler's net worth?: The estimated net worth of Lukas Scheibler is at least $3.27 million as of December 1st, 2023. Dr. Scheibler owns 68,299 shares of Apellis Pharmaceuticals stock worth more than $3,273,571 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Scheibler may own. Learn More about Lukas Scheibler's net worth.
How do I contact Lukas Scheibler?: The corporate mailing address for Dr. Scheibler and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Lukas Scheibler's contact information.
Has Lukas Scheibler been buying or selling shares of Apellis Pharmaceuticals?: Lukas Scheibler has not been actively trading shares of Apellis Pharmaceuticals in the last ninety days. Most recently, Lukas Scheibler sold 10,000 shares of the business's stock in a transaction on Friday, December 1st. The shares were sold at an average price of $60.00, for a transaction totalling $600,000.00. Following the completion of the sale, the insider now directly owns 68,299 shares of the company's stock, valued at $4,097,940. Learn More on Lukas Scheibler's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 55 times. They sold a total of 832,985 shares worth more than $51,199,751.25. The most recent insider tranaction occured on April, 8th when insider Pascal Deschatelets sold 69,107 shares worth more than $3,743,526.19. Insiders at Apellis Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Lukas Scheibler Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2023	Sell	10,000	$60.00	$600,000.00	68,299
5/27/2022	Sell	10,000	$43.00	$430,000.00	40,358
4/4/2022	Sell	3,504	$56.96	$199,587.84	52,233
4/1/2022	Sell	11,496	$55.05	$632,854.80	52,233
2/11/2022	Sell	1,666	$46.80	$77,968.80
2/8/2022	Sell	10,000	$45.00	$450,000.00
1/31/2022	Sell	1,233	$38.47	$47,433.51
6/10/2021	Sell	3,417	$60.00	$205,020.00
5/24/2018	Buy	2,935	$20.37	$59,785.95

Lukas Scheibler Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $47.93

$47.02

$49.31

50 Day Range

MA: $58.61

$47.51

$71.73

2 Week Range

Now: $47.93

$19.83

$94.75

Volume

1,092,999 shs

Average Volume

1,479,269 shs

Market Capitalization

$5.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad